Skip to content

Investigator

Tim Lahm

NATIONAL JEWISH HEALTH · funded by NHLBI, VA

Companies
2

Resolved onto their grants.

Grants
5

Federal awards on file.

Non-dilutive funding
$1.1M

Summed across those awards.

First award
Jan 1, 2014

Latest Jun 1, 2026.

Companies from this work

Pre-ticker companies the crosswalk resolved onto a grant filed under this investigator. Momentum shows for the therapeutic areas your seat covers; open a dossier for the full crosswalk.

Grant record

Federal awards filed under this investigator name, newest first. Each links to the public record where the awarding agency publishes one.

  1. R13

    Pulmonary Vascular Disease: The Vascular Niche and its Interactions in Lung Homeostasis and Disease

    $30k

    Jun 1, 2026NHLBINATIONAL JEWISH HEALTHNIH RePORTER · 11390961 (opens the source filing in a new tab)

  2. P01

    Androgen signaling in asthma

    $354k

    Aug 1, 2021NHLBIINDIANA UNIVERSITY INDIANAPOLISNIH RePORTER · 11085935 (opens the source filing in a new tab)

  3. R01

    Mechanisms of right ventricle adaptation to pulmonary hypertension

    $726k

    Sep 1, 2019NHLBINATIONAL JEWISH HEALTHNIH RePORTER · 11192285 (opens the source filing in a new tab)

  4. I01

    Estrogen Receptor-alpha Effects on Right Ventricular Vascular Density and Angiogenesis in Pulmonary Hypertension

    Jan 1, 2014VAVA EASTERN COLORADO HEALTH CARE SYSTEMNIH RePORTER · 10804445 (opens the source filing in a new tab)

  5. I01

    Estrogen Receptor-alpha Effects on Right Ventricular Vascular Density and Angiogenesis in Pulmonary Hypertension

    Jan 1, 2014VAVA EASTERN COLORADO HEALTH CARE SYSTEMNIH RePORTER · 11258402 (opens the source filing in a new tab)

This page aggregates public U.S. federal grant records filed under one investigator name and the companies Biodatica has resolved onto them. Names are shown as the awarding agency filed them; grant awards are non-dilutive federal funding, not equity or valuation. Distinct people who file under the same name would appear together here. It is informational only and not investment advice. Methodology · Data sources